2

Take-home message
Living in tropical Australia was associated with NTM acquisition whilst long-term azithromycin was protective in CF. 3 
Word count, 1195
To the editor: Improved survival rates and increased treatment intensity of people with cystic fibrosis (CF) has been accompanied by the rising incidence of multi-antibiotic resistant and difficult to treat respiratory pathogens, including non-tuberculous mycobacteria (NTM) [1] . NTM epidemiology in CF varies globally with a prevalence of >20% in some geographical locations [2] . In particular, there are concerns that active NTM disease from rapidly growing mycobacteria (Mycobacterium abscessus complex) may be increasing and causing accelerated pulmonary decline [3, 4] . NTM are found naturally in ecological niches such as soil and water and susceptible individuals may also acquire infection from potable water in their homes [5, 6] . Recent reports demonstrate person-to-person transmission [7, 8] , which might occur via fomites and cough aerosols [8] and further emphasise the potential clinical importance of these organisms.
The principle aim of this observational study was to determine predictors of NTM Patients were stratified into one of two cohorts depending on whether they were NTM 4 positive or negative (naïve) based on sputum culture results, which were available for 399/434 (92%) patients. The remaining patients (n=35) who were not screened for NTM during the study period were classed as NTM naïve. Mycobacterial culture and species identification methods are described previously [9] . The date of NTM acquisition was defined as the date of first positive culture identified by the Queensland Mycobacterial Reference Laboratory or the referring CF centre (if patient was transferred to TPCH). Active NTM disease was defined according to American Thoracic Society guidelines [10] .
Clinical and demographic data ( Table 1) and atmospheric moisture availability [11] . In our study, NTM was detected in 54/375 (14%) patients with CF. In a multivariable logistic regression, the odds of NTM acquisition were 2.5 (95% confidence interval, 1.2-5.4) times higher (Table 1) NTM lung disease was reported to occur in 69% of M. abscessus infected CF patients [4] . Here, active NTM disease was diagnosed in 14/70 (20%) tropical patients and 11/305 (4%) sub-tropical patients (P<0.001) and overall, 23/25 (92%) people diagnosed with lung disease were positive for M. abscessus complex.
Markers for severe CF disease (e.g. pancreatic insufficiency, minimal CFTR function, P. aeruginosa infection) have also been reported to coincide with higher rates of NTM infection [4] . Whilst we did not find that such markers were associated with NTM acquisition ( Table 1) after adjustment for other variables, we found that macrolide treatment for at least 6 months in the prior year was associated with reduced NTM acquisition. The adjusted odds of NTM acquisition was 15.4 (95% confidence interval, 7.8-30.5) times higher in those who were not prescribed azithromycin compared to those that were ( Table 1 ). The role of macrolide antibiotic use in NTM infection remains controversial with one study suggesting enhanced risk of NTM and others refuting this claim [13] [14] [15] .
The impact of NTM infection and patient survival is currently unclear. One study observed that a quarter of patients with M. abscessus complex died or were lung transplanted [12] . Here, neither being NTM positive (hazards ratio, 0.6; 95% confidence interval, 0.2-1.4; P=0.2) nor being diagnosed with active NTM disease (hazards ratio, 0.6; 95% confidence interval, 0.2-2.6; P=0.5) were associated with an increased risk of death/lung transplantation.
Although this study is limited by its retrospective cross-sectional design, we found that living in the tropical zone of Australia was independently associated with NTM 8 acquisition whilst long-term azithromycin treatment was protective. Tropical patients were more likely to acquire more than one NTM species and have a diagnosis of active NTM disease. Australian population-based studies are required to determine specific host, socio-ecological, economic, climatic and environmental factors that affect acquisition and development of active NTM disease in CF. 
